{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:45Z","timestamp":1792685925246,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Hematopoietic stem cell transplantation and gene therapy are the only curative therapies for severe combined immunodeficiency (SCID). In patients lacking a matched donor, TCR\u03b1\u03b2\/CD19-depleted haploidentical family donor transplant (TCR\u03b1\u03b2-HaploSCT) is a promising strategy. Conditioned transplant in SCID correlates to better myeloid chimerism and reduced immunoglobulin dependency. We studied transplant outcome in SCID infants according to donor type, specifically TCR\u03b1\u03b2-HaploSCT, and conditioning, through retrospective cohort analysis of 52 consecutive infants with SCID transplanted between 2013 and 2020. Median age at transplant was 5.1\u00a0months (range, 0.8\u201316.6). Donors were TCR\u03b1\u03b2-HaploSCT (<jats:italic>n<\/jats:italic>\u2009=\u200916, 31.4%), matched family donor (MFD, <jats:italic>n<\/jats:italic>\u2009=\u200915, 29.4%), matched unrelated donor (MUD, <jats:italic>n<\/jats:italic>\u2009=\u20099, 17.6%), and matched unrelated cord blood (CB, <jats:italic>n<\/jats:italic>\u2009=\u200911, 21.6%). Forty-one (80%) received fludarabine\/treosulfan-based conditioning, 3 (6%) had alemtuzumab only, and 7 (14%) received unconditioned infusions. For conditioned transplants (<jats:italic>n<\/jats:italic>\u2009=\u200941), 3-year overall survival was 91% (95% confidence interval, 52\u201399%) for TCR\u03b1\u03b2-HaploSCT, 80% (41\u201398%) for MFD, 87% (36\u201398%) for MUD, and 89% (43\u201398%) for CB (<jats:italic>p<\/jats:italic>\u2009=\u20090.89). Cumulative incidence of grade II\u2013IV acute graft-versus-host disease was 11% (2\u201379%) after TCR\u03b1\u03b2-HaploSCT, 0 after MFD, 29% (7\u2013100%) after MUD, and 11% (2\u201379%) after CB (<jats:italic>p<\/jats:italic>\u2009=\u20090.10). 9\/10 patients who received alemtuzumab-only or unconditioned transplants survived. Myeloid chimerism was higher following conditioning (median 47%, range 0\u2013100%) versus unconditioned transplant (median 3%, 0\u20139%) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), as was the proportion of immunoglobulin-free long-term survivors (<jats:italic>n<\/jats:italic>\u2009=\u200929\/36, 81% vs <jats:italic>n<\/jats:italic>\u2009=\u20094\/9, 54%) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). TCR\u03b1\u03b2-HaploSCT has comparable outcome to MUD and is a promising alternative donor strategy for infants with SCID lacking MFD. This study confirms that conditioned transplant offers better myeloid chimerism and immunoglobulin freedom in long-term survivors.<\/jats:p>","DOI":"10.1007\/s10875-022-01239-z","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T13:02:36Z","timestamp":1647694956000},"page":"851-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["TCR\u03b1\u03b2-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined Immunodeficiency"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-104X","authenticated-orcid":false,"given":"Christo","family":"Tsilifis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Han","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Nademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hambleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleri J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Abinun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Gennery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"issue":"17","key":"1239_CR1","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","volume":"132","author":"E Haddad","year":"2018","unstructured":"Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, et al. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018;132(17):1737\u201349.","journal-title":"Blood"},{"issue":"5","key":"1239_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1401177","volume":"371","author":"S-Y Pai","year":"2014","unstructured":"Pai S-Y, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009. N Engl J Med. 2014;371(5):434\u201346.","journal-title":"N Engl J Med"},{"key":"1239_CR3","doi-asserted-by":"crossref","unstructured":"Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr [Internet]. 2009 Dec;155(6):834\u2013840.e1. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347609007471","DOI":"10.1016\/j.jpeds.2009.07.049"},{"key":"1239_CR4","doi-asserted-by":"crossref","unstructured":"Grunebaum E, Mazzolari E, Porta F, Dallera D, Atkinson A, Reid B, et al. Bone marrow transplantation for severe combined immune deficiency. J Am Med Assoc [Internet]. 2006 Feb 1;295(5):508\u201318. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16449616","DOI":"10.1001\/jama.295.5.508"},{"issue":"7","key":"1239_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/1744666X.2019.1612746","volume":"15","author":"R Elfeky","year":"2019","unstructured":"Elfeky R, Lazareva A, Qasim W, Veys P. Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. Expert Rev Clin Immunol [Internet]. 2019;15(7):735\u201351. https:\/\/doi.org\/10.1080\/1744666X.2019.1612746.","journal-title":"Expert Rev Clin Immunol [Internet]"},{"issue":"5","key":"1239_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2141.2011.08994.x","volume":"156","author":"R Chiesa","year":"2012","unstructured":"Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJJ, Zhan H, et al. Omission of in vivo T-cell depletion promotes rapid expansion of na\u00efve CD4 + cord blood lymphocytes and restores adaptive immunity within 2months after unrelated cord blood transplant. Br J Haematol. 2012;156(5):656\u201366.","journal-title":"Br J Haematol"},{"issue":"3","key":"1239_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bbmt.2016.12.635","volume":"23","author":"A Laberko","year":"2017","unstructured":"Laberko A, Bogoyavlenskaya A, Shelikhova L, Shekhovtsova Z, Balashov D, Voronin K, et al. Risk factors for and the clinical impact of cytomegalovirus and Epstein-Barr virus infections in pediatric recipients of TCR-\u03b1\/\u03b2\u2013 and CD19-depleted grafts. Biol Blood Marrow Transplant [Internet]. 2017;23(3):483\u201390. https:\/\/doi.org\/10.1016\/j.bbmt.2016.12.635.","journal-title":"Biol Blood Marrow Transplant [Internet]"},{"issue":"11","key":"1239_CR8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.bbmt.2015.07.008","volume":"21","author":"D Balashov","year":"2015","unstructured":"Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCR\u03b1\u03b2 and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant [Internet]. 2015;21(11):1955\u201362. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.008.","journal-title":"Biol Blood Marrow Transplant [Internet]"},{"issue":"5","key":"1239_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10875-019-00648-x","volume":"39","author":"T Brettig","year":"2019","unstructured":"Brettig T, Smart J, Choo S, Mechinaud F, Mitchell R, Raj TS, et al. Use of TCR \u03b1+\u03b2+\/CD19+\u2013depleted haploidentical hematopoietic stem cell transplant is a viable option in patients with primary immune deficiency without matched sibling donor. J Clin Immunol. 2019;39(5):505\u201311.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1239_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","volume":"141","author":"RM Shah","year":"2018","unstructured":"Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, et al. T-cell receptor \u03b1\u03b2+ and CD19+ cell\u2013depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol [Internet]. 2018;141(4):1417-1426.e1. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.008.","journal-title":"J Allergy Clin Immunol [Internet]"},{"key":"1239_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41409-020-01152-2","volume":"3","author":"SH Lum","year":"2020","unstructured":"Lum SH, Sobh A, Carruthers K, Nademi Z, Watson H, McNaughton P, et al. Improved survival and graft function in ex vivo T-cell depleted haploidentical hematopoietic cell transplantation for primary immunodeficiency. Bone Marrow Transplant [Internet]. 2020;3:4\u20138. https:\/\/doi.org\/10.1038\/s41409-020-01152-2.","journal-title":"Bone Marrow Transplant [Internet]"},{"key":"1239_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","author":"AC Lankester","year":"2021","unstructured":"Lankester AC, Albert MH, Booth C, Gennery AR, G\u00fcng\u00f6r T, H\u00f6nig M, et al. EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transplant [Internet]. 2021. https:\/\/doi.org\/10.1038\/s41409-021-01378-8.","journal-title":"Bone Marrow Transplant [Internet]"},{"issue":"1","key":"1239_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol [Internet]. 2012;1(1):36. https:\/\/doi.org\/10.1186\/2162-3619-1-36.","journal-title":"Exp Hematol Oncol [Internet]"},{"issue":"1","key":"1239_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0385-3","volume":"11","author":"N Brodszki","year":"2016","unstructured":"Brodszki N, Turkiewicz D, Toporski J, Truedsson L, Dykes J. Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions. Orphanet J Rare Dis [Internet]. 2016;11(1):1\u20138. https:\/\/doi.org\/10.1186\/s13023-016-0385-3.","journal-title":"Orphanet J Rare Dis [Internet]"},{"key":"1239_CR15","doi-asserted-by":"crossref","unstructured":"Cowan MJ, Gennery AR. Radiation-sensitive severe combined immunodeficiency: the arguments for and against conditioning before hematopoietic cell transplantation\u2014what to do? J Allergy Clin Immunol [Internet]. 2015 Nov;136(5):1178\u201385. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674915005898","DOI":"10.1016\/j.jaci.2015.04.027"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01239-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-022-01239-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01239-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T16:12:51Z","timestamp":1654272771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-022-01239-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1007\/s10875-022-01239-z","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable (retrospective data collection only).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Prior written consent from parents was given for data collection, analysis, and dissemination.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Prior written consent from parents was given for data collection, analysis, and dissemination.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}